MK-677 vs Ipamorelin: Two Different Routes to Growth Hormone

MK-677 and Ipamorelin are two of the most discussed compounds in growth hormone research, and “MK-677 vs Ipamorelin” is one of the most searched comparisons in the field. They are often spoken about as if they were interchangeable. They are not. Both act on the same receptor, the ghrelin receptor, and both make the pituitary release growth hormone. But one is a small, non-peptide molecule designed to be taken by mouth and last all day, while the other is a five-amino-acid peptide designed to produce a short, clean pulse. That difference in design shapes almost everything about how they behave in research.

This guide explains what each compound is, where it came from, how each works, what the key studies in animals and people found, and how they compare. It is an educational comparison of research findings, not medical advice. Crown Peptides supplies Ipamorelin for laboratory research use only; we do not sell MK-677.

The Short Answer

Ipamorelin is a synthetic pentapeptide that acts on the ghrelin receptor to trigger a brief, selective pulse of growth hormone, with little effect on stress hormones. It is broken down quickly and is not active by mouth.

MK-677, also called ibutamoren, is a small non-peptide molecule that acts on the same receptor. It is active by mouth and long-lasting, producing a sustained rise in growth hormone and IGF-1 over the whole day. It has more human trial data than Ipamorelin, including a year-long trial in older adults, which showed increases in lean mass alongside rises in blood sugar and appetite.

Growth Hormone in Plain English

What growth hormone does

Growth hormone is a protein made by the pituitary gland. In children it drives growth. In adults it helps maintain muscle and bone, influences how fat is stored and burned, and affects blood sugar. Much of its effect is carried out by IGF-1, a growth factor it tells the liver and other tissues to produce.

How its release is controlled

Growth hormone release is controlled by two “go” signals and one “stop” signal. GHRH from the hypothalamus acts on the GHRH receptor. Ghrelin, and compounds such as MK-677 and Ipamorelin, act on the ghrelin receptor. Somatostatin applies the brakes. IGF-1 feeds back to slow further release.

Pulses, not a steady stream

Growth hormone is released in bursts throughout the day and night, with the largest pulse usually shortly after falling asleep. This pulsatile pattern is thought to matter for how tissues respond.

The decline with age

Growth hormone secretion falls steadily through adult life, a change sometimes called the somatopause. IGF-1 falls with it. Much secretagogue research, including the MK-677 trial in older adults, has focused on this decline.

One Receptor, Two Molecules

The ghrelin receptor

Both compounds act on the growth hormone secretagogue receptor, now known as the ghrelin receptor. It is found on growth hormone-producing cells in the pituitary and on neurons in the hypothalamus that control growth hormone release and appetite. Its natural partner, ghrelin, is the body’s hunger hormone, made mainly in the stomach.

Why two very different molecules fit one receptor

Receptors recognise shapes and chemical features, not the families that molecules happen to belong to. A peptide and a small organic molecule can both fit the same binding pocket if they present the right chemical features in the right arrangement. The ghrelin receptor story is a classic example: it was first found using peptides, then targeted with small molecules designed to mimic them.

The Shared Origin Story

The peptides came first

In the late 1970s and 1980s, Cyril Bowers and colleagues developed synthetic growth hormone releasing peptides, including GHRP-6, which released growth hormone through a receptor nobody had yet identified. A 1998 review by Camanni, Ghigo and Arvat described how this family of peptides worked and how they synergised with GHRH (PMID: 9465289).

Merck’s small molecules

Peptides are broken down in the gut, so they cannot easily be taken by mouth. Researchers at Merck set out to find small molecules that did the same job but could be swallowed. Using GHRP-6 as their template, they developed a series of compounds culminating in MK-0677, later named ibutamoren. A 2005 review in Endocrine Reviews by Smith and colleagues told the story of how growth hormone secretagogues were developed (PMID: 15814848). In 1996, Merck scientists used these compounds to clone the receptor itself, and in 1999 ghrelin, its natural hormone, was discovered in Japan.

Novo Nordisk’s selective peptide

Meanwhile, Novo Nordisk in Denmark was refining the peptide approach. Earlier peptides such as GHRP-2 and GHRP-6 also raised the stress hormones ACTH and cortisol. In 1998, Raun and colleagues introduced Ipamorelin, which released growth hormone with potency similar to GHRP-6 but without significantly raising ACTH or cortisol, even at amounts far above those needed for growth hormone release (PMID: 9849822). The authors called it the first selective growth hormone secretagogue.

Ipamorelin in Detail

Structure

Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2. It contains unusual building blocks, including alpha-aminoisobutyric acid and two D-amino acids, which help it resist breakdown and fit the receptor.

A short, clean pulse

In a 1999 pharmacokinetic study in healthy volunteers, Ipamorelin had a terminal half-life of about two hours and produced a single episode of growth hormone release, peaking around 40 minutes after infusion and returning to baseline (PMID: 10496658). That pulse-like pattern resembles the body’s natural growth hormone rhythm.

Research findings

In animal research, Ipamorelin increased bone growth and protected muscle strength and bone formation against high-dose glucocorticoids in rats (PMID: 11735244). In a 2014 phase 2 trial in 117 patients after bowel surgery, it was well tolerated, though its effect on recovery of gut function did not reach statistical significance (PMID: 25331030). Our Ipamorelin guide covers its research in full.

MK-677 in Detail

Structure

MK-677 is not a peptide. It is a small organic molecule built on a spiropiperidine core, designed to mimic the key features of peptide secretagogues while surviving digestion.

Sustained action

Unlike Ipamorelin, MK-677 is active by mouth and acts over roughly a day, producing sustained increases in growth hormone pulses and in IGF-1.

The year-long trial in older adults

The most informative MK-677 study is a 2008 randomised, placebo-controlled trial in the Annals of Internal Medicine by Nass and colleagues at the University of Virginia (PMID: 18981485, PMC2757071). Sixty-five healthy adults aged 60 to 81 received MK-677 or placebo daily for a year. MK-677 raised growth hormone and IGF-1 into the range typical of young adults and increased fat-free mass by about 1.1 kg, while it fell slightly with placebo. But the gain in lean mass did not translate into changes in strength or function. Fasting blood glucose rose, insulin sensitivity fell, and appetite increased, although the appetite effect subsided within a few months. Cortisol rose modestly.

Hip fracture recovery

In a 2011 trial in older adults recovering from hip fracture, MK-677 raised IGF-1 and improved gait speed on one measure, but did not significantly change its main measure of stair climbing power (PMID: 21067829).

MK-677 vs Ipamorelin: Side by Side

Chemical family

Ipamorelin is a peptide. MK-677 is a small non-peptide molecule. That is why “is MK-677 a peptide?” is such a common question: it is not, even though it acts like one.

Route in research

MK-677 was designed to be active by mouth. Ipamorelin, like most peptides, is broken down in the gut.

Duration and pattern

Ipamorelin produces a short pulse of growth hormone lasting a couple of hours. MK-677 produces a sustained elevation over the day. This is the single biggest difference between them.

Selectivity

Ipamorelin was designed specifically to avoid raising ACTH and cortisol. MK-677 produced a modest rise in cortisol in the year-long trial.

Appetite and blood sugar

Increased appetite and rises in blood sugar, with reduced insulin sensitivity, were documented with MK-677 in older adults. Ipamorelin’s appetite effect is generally described as less prominent, though it acts on the same hunger hormone receptor.

Human evidence

MK-677 has more human trial data, including a year-long randomised trial. Ipamorelin has human pharmacokinetic data and a phase 2 surgical trial.

IGF-1: The Downstream Messenger

Much of what growth hormone does is carried out by IGF-1, insulin-like growth factor 1. Growth hormone tells the liver to produce IGF-1, which circulates in the blood, and tissues such as muscle and bone also make their own. IGF-1 drives cell growth and protein synthesis and is the main reason growth hormone builds tissue. Because growth hormone itself is released in short pulses and cleared quickly, IGF-1, which is much more stable, is often used as a summary measure of overall growth hormone activity. In the MK-677 trial in older adults, IGF-1 rose into the young-adult range, confirming a sustained increase in growth hormone signalling. Researchers who want to study IGF-1 signalling directly can use IGF-1 LR3.

Feedback: Why the Body Stays in Control

One of the key features of growth hormone secretagogues is that they work through the body’s own release machinery and remain subject to its feedback controls. IGF-1 and somatostatin act as brakes: as growth hormone and IGF-1 rise, the brakes strengthen. This means secretagogues cannot push growth hormone indefinitely in the way directly supplying growth hormone could. With a sustained compound such as MK-677, however, the system is stimulated continuously, which may explain why IGF-1 stays elevated and why metabolic effects such as rising blood sugar appear. With a pulse-producing compound such as Ipamorelin, the system is stimulated briefly and then allowed to reset.

Bone and the Growth Hormone Axis

Growth hormone and IGF-1 influence bone as well as muscle. In the MK-677 trial, markers of bone turnover increased, consistent with increased bone remodelling. In rat research, Ipamorelin increased bone growth and counteracted glucocorticoid-induced loss of bone formation. Bone effects take a long time to become measurable, so they are best studied in longer research designs, and they are a reminder that the growth hormone axis affects the whole musculoskeletal system.

The Appetite Connection

Because both compounds act on the ghrelin receptor, the receptor for the body’s hunger hormone, effects on appetite are part of their biology. Ghrelin rises before meals and signals hunger through neurons in the hypothalamus that produce neuropeptide Y and agouti-related peptide. Increased appetite was one of the most frequent effects of MK-677 in the year-long trial, although it faded within a few months. Ipamorelin’s appetite effect is generally described as less prominent than that of GHRP-6, the peptide best known for stimulating hunger. For researchers, measuring food intake is essential whenever these compounds are studied, because changes in body composition could otherwise simply reflect eating more.

The Sleep Connection

Ghrelin and the growth hormone system are closely tied to sleep. In a 2003 study at the Max Planck Institute of Psychiatry, giving ghrelin to healthy men in the evening increased deep, slow-wave sleep and raised growth hormone through the night (PMID: 12388174). Ghrelin receptor agonists are therefore of interest in sleep research as well as growth hormone research, and a sustained-acting compound and a pulse-producing one might be expected to interact with sleep differently. Our sleep research guide explores this area.

Why the Pattern of Growth Hormone Matters

Growth hormone is naturally released in pulses, with the largest during deep sleep. Research in animals has shown that the pattern of growth hormone, pulsed or continuous, can itself change which genes are active in tissues such as the liver. A compound that produces short pulses, like Ipamorelin, and one that produces sustained elevation, like MK-677, may therefore have different downstream effects even at similar overall exposure. A 2018 review in Sexual Medicine Reviews noted that secretagogues promote pulsatile release that remains subject to the body’s feedback controls, and discussed reported effects including increased appetite and blood sugar (PMID: 28400207, PMC5632578).

What the Evidence Does Not Show

It is worth being clear about the limits of the evidence for both compounds. The MK-677 trials showed increases in lean mass and IGF-1, but not improvements in strength or function in older adults, and they documented metabolic effects that would need careful consideration. Ipamorelin’s human data are limited to pharmacokinetic studies and a surgical trial, so its long-term effects in people are unknown. Neither compound is a licensed medicine in the UK, and both are prohibited in sport under the World Anti-Doping Agency’s rules on growth hormone secretagogues. Online claims about either often go well beyond what published research supports.

Combining a Ghrelin Receptor Agonist With GHRH

A common research question is how a ghrelin receptor agonist interacts with a GHRH analogue. Because the two act on different receptors that both trigger growth hormone release, their effects combine, and research has long established that growth hormone releasing peptides act synergistically with GHRH in living systems. Ipamorelin’s short action matches the short action of CJC-1295 without DAC, which is why the two are paired. MK-677’s sustained action would pair very differently. Our article the two-pathway approach explains the combination.

Choosing Between Them in Research

When Ipamorelin fits

Ipamorelin suits studies that need a brief, selective growth hormone pulse, studies of the ghrelin receptor without stress hormone effects, and combination studies with GHRH analogues, where its short action matches theirs. It is combined with CJC-1295 in the CJC-1295 (No DAC) + Ipamorelin (Blend).

When MK-677’s profile is the question

Research questions about sustained growth hormone and IGF-1 elevation, and about oral secretagogues, centre on MK-677 and its clinical literature.

Designing comparisons

Fair comparisons require matching overall exposure, measuring growth hormone frequently enough to capture pulses, and measuring IGF-1, blood sugar, insulin, cortisol and appetite alongside body composition and function.

Research Models for Secretagogues

Secretagogue research uses several kinds of model. Pituitary cells grown in the laboratory show direct effects on growth hormone release. Animal studies, particularly in rats and pigs, show effects on the whole system, including the hypothalamus, appetite and body composition; Ipamorelin’s original selectivity work was done in pigs. Human pharmacokinetic studies show how quickly a compound acts and is cleared, and randomised trials show effects on body composition, metabolism and function over time. Each model answers a different question, and a full understanding of any secretagogue draws on all of them.

The Technical Breakdown: Receptor Pharmacology

GHS-R1a signalling

The ghrelin receptor, GHS-R1a, is a G protein-coupled receptor that mainly activates Gq, raising calcium inside the cell and triggering growth hormone release. It is also unusual for signalling at a low level even without anything bound.

Hypothalamic effects

At the hypothalamus, ghrelin receptor agonists increase GHRH release and reduce somatostatin, amplifying the pituitary response, and stimulate appetite circuits.

Why selectivity differs

Small differences in how a compound binds and activates the receptor, and whether it acts on other targets, can change its effects on stress hormones and prolactin. Ipamorelin’s selectivity was a deliberate design goal.

Oral activity

MK-677’s small size, fat solubility and resistance to digestive enzymes allow it to be absorbed from the gut, something peptides like Ipamorelin cannot easily achieve.

Why “Selective” Matters So Much

Early growth hormone releasing peptides did more than release growth hormone. GHRP-2 and GHRP-6 also raised ACTH and cortisol, the body’s stress hormones, and sometimes prolactin. For researchers, those extra effects are a problem: if a study finds a change in muscle, fat or behaviour, it becomes hard to tell whether growth hormone or stress hormones caused it. Ipamorelin was designed to remove that ambiguity. In the 1998 pig study, it did not significantly raise ACTH or cortisol even at amounts more than 200 times those needed for growth hormone release. MK-677 produced a modest rise in cortisol in older adults. Selectivity therefore shapes not just what a compound does but how interpretable a study using it will be.

A Timeline of the Ghrelin Receptor Story

The story of these two compounds is a story about one receptor. In the late 1970s, Cyril Bowers began developing synthetic growth hormone releasing peptides. In 1984, GHRP-6 was described in detail. Through the late 1980s and early 1990s, Merck used GHRP-6 as a template to develop small molecules that could be swallowed, leading to MK-677. In 1996, Merck scientists used these compounds to clone the growth hormone secretagogue receptor. In 1998, Novo Nordisk introduced Ipamorelin as the first selective secretagogue. In 1999, Masayasu Kojima and Kenji Kangawa discovered ghrelin, finally revealing the natural hormone the receptor had been built for. And in the 2000s, trials of MK-677 in older adults tested whether sustained stimulation of this system could counter age-related changes. Few receptors have been studied from so many angles.

Why Quality Matters

Ipamorelin’s unusual building blocks must be exactly right, and a 2018 anti-doping study found black market products containing a glycine-extended version of Ipamorelin, detectable only by mass spectrometry (PMID: 29864719). Every batch of Ipamorelin supplied by Crown Peptides comes with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity. Published certificates are on our Lab Reports page.

Related Compounds and Reading

Other ghrelin receptor agonists include GHRP-2 and GHRP-6. GHRH analogues include Sermorelin, Tesamorelin and CJC-1295 with DAC. Downstream, IGF-1 LR3 is studied directly. Read Ipamorelin vs GHRP-2, GHRP-6 vs Ipamorelin and best peptides for muscle research, and browse the endocrine and hormonal research peptides category.

MK-677 vs Ipamorelin: Questions, Answered

Is MK-677 a peptide or a SARM?

Neither. MK-677, or ibutamoren, is a small non-peptide molecule that acts on the same receptor as peptide secretagogues. It is often grouped with SARMs online, but SARMs act on the androgen receptor, which MK-677 does not.

What is the main difference between MK-677 and Ipamorelin?

Duration and pattern. Ipamorelin produces a short, selective pulse of growth hormone; MK-677 produces a sustained rise over the day.

Which has more human research?

MK-677, including a year-long randomised trial in older adults.

Does MK-677 affect blood sugar?

In the year-long trial in older adults, MK-677 raised fasting blood glucose and reduced insulin sensitivity.

How long does Ipamorelin last?

In human pharmacokinetic research, it had a terminal half-life of about two hours, with growth hormone peaking around 40 minutes after infusion.

Do secretagogues raise growth hormone forever?

No. They work through the body’s own release machinery and feedback controls, so IGF-1 and somatostatin act as brakes as levels rise. That is a key difference from supplying growth hormone directly.

Where can I read the studies?

Every study in this guide is linked to its PubMed record, where the abstract and often the full paper can be read.

Can Ipamorelin be taken by mouth?

Like most peptides, Ipamorelin is broken down in the digestive system, so it is not active by mouth. MK-677 was specifically designed to be.

Why is MK-677 called a ghrelin mimetic?

Because it mimics ghrelin’s action at the ghrelin receptor, even though it looks nothing like ghrelin chemically.

Which is better for research, MK-677 or Ipamorelin?

Neither is universally better. Ipamorelin suits studies needing a brief, selective pulse; MK-677’s profile suits questions about sustained, oral stimulation of the growth hormone axis.

Is ghrelin the same as MK-677?

No. Ghrelin is the natural 28-amino-acid hunger hormone; MK-677 is a synthetic small molecule that acts on ghrelin’s receptor.

What is IGF-1?

Insulin-like growth factor 1, produced mainly by the liver in response to growth hormone. It carries out much of growth hormone’s tissue-building effect and is used as a summary measure of growth hormone activity.

Why does IGF-1 stay high with MK-677?

Because MK-677 acts over the whole day, stimulating growth hormone release continuously rather than in a single brief pulse.

Are MK-677 and Ipamorelin legal in the UK?

Neither is a controlled drug in the UK, and neither is a licensed medicine. Both are prohibited in sport. See are peptides legal in the UK.

Does Crown Peptides sell MK-677?

No. Crown Peptides supplies Ipamorelin, along with other peptide secretagogues, for laboratory research.

Do MK-677 and Ipamorelin increase appetite?

Both act on the ghrelin receptor, the hunger hormone’s receptor. Increased appetite was a frequent effect of MK-677 in older adults; Ipamorelin’s appetite effect is generally described as less prominent.

Why was Ipamorelin developed?

To release growth hormone without the stress hormone effects of earlier peptides such as GHRP-2 and GHRP-6.

Same Door, Different Keys

MK-677 and Ipamorelin unlock the same receptor, but they were cut for different purposes. Ipamorelin is a precision peptide designed for a brief, selective pulse that echoes the body’s natural rhythm. MK-677 is a small molecule designed for oral use and all-day action, with a larger human evidence base that shows both its effects on body composition and its effects on blood sugar and appetite. Understanding that difference, pulse versus plateau, peptide versus small molecule, selective versus broader, is the key to understanding what each compound can and cannot tell researchers about the growth hormone system, and to choosing the right one for a given study.

Explore Ipamorelin from Crown Peptides, every batch HPLC and mass spectrometry verified and dispatched from the UK.